Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Organon & Co.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
NYSE · Pharmaceutical Preparations
Prev close 13.68 · gapped below the open, then crossed back over prior close. High/low 13.68 at 11:30 am ET, 13.66 at 9:30 am ET.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“In March 2025, we acquired from Biogen the regulatory and commercial rights in the United States for Tofidence , a biosimilar to Actemra 2 (tocilizumab), for intravenous infusion.”
FILING10-K0001628280-26-011125cik 0001821825
“Sales of Emgality, a medicine for the preventive treatment of migraine, increased 63% for the year ended December 31, 2025, compared to 2024, as a result of our acquisition of the distribution and promotion rights from Lilly in 2024 in certain markets outside of the United States.”
FILING10-K0001628280-26-011125cik 0001821825
“As part of our post-spinoff plan to further optimize our manufacturing and supply network, we will continue to separate our supply chain through planned exits from supply agreements with Merck through 2031.”
FILING10-K0001628280-26-011125cik 0001821825
“On October 28, 2024, Organon acquired Dermavant, a company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology.”
FILING10-K0001628280-26-011125cik 0001821825
“In January 2026, the Company divested the Jada System to Laborie for an aggregate payment of up to $ 465 million, comprised of consideration of $ 440 million, subject to certain customary closing adjustments, including inventory value, plus potential earnout payments of up to $ 25 million based on the achievement of certain 2026 net sales targets.”
FILING10-K0001628280-26-011125cik 0001821825
“In January 2026, we divested the Jada System to Laborie for an aggregate payment of up to $465 million, comprised of consideration of $440 million, subject to certain closing adjustments, plus potential earnout payments of up to $25 million based on the achievement of certain 2026 net sales targets.”
FILING10-K0001628280-26-011125cik 0001821825
“Under the agreement, Samsung Bioepis is responsible for preclinical and clinical development, process development and manufacturing, clinical trials and registration of product candidates, and the Company has an exclusive license for worldwide commercialization with certain geographic exceptions specified on a product-by-product basis.”
FILING10-K0001628280-26-011125cik 0001821825
“In September 2024, we entered into license and supply agreements with Centergene, pursuant to which we acquired the exclusive commercialization rights to Centergene's investigational asset, SJ02, in China.”
FILING10-K0001628280-26-011125cik 0001821825
“For example, in October 2023, Organon notified us of its intent to terminate the Organon License Agreement, which we assumed pursuant to the ObsEva IP Acquisition Agreement.”
FILING10-K0001104659-26-030872cik 0000791908disclosed by XOMA
“Under the terms of the agreement with Biogen, we paid an upfront payment of $51 million in July 2025, and are obligated to pay tiered royalty payments based on net sales and tiered annual net sales milestone payments of up to $45 million from a previous in-license arrangement with Bio-Thera Solutions Ltd., the product developer for Tofidence .”
FILING10-K0001628280-26-011125cik 0001821825
“For the year ended December 31, 2025, we recognized $6 million in acquired in-process research and development and milestones, related to the exit of our agreement with Centergene, due to the evolving fertility landscape in China.”
FILING10-K0001628280-26-011125cik 0001821825
“For the year ended December 31, 2024, acquired in-process research and development and milestones of $81 million primarily represented the research and development milestones of $70 million for our agreement with Henlius and $10 million for our agreement with Cirqle, which were determined to be probable of being achieved.”
FILING10-K0001628280-26-011125cik 0001821825
“On February 19, 2026 Organon entered into an exclusive license agreement with Sebela Pharmaceuticals for the global rights to Miudella ®2 , a hormone-free copper intrauterine device ("IUD") which was approved by the FDA on February 24, 2025.”
FILING10-K0001628280-26-011125cik 0001821825
“For the year ended December 31, 2024, acquired in-process research and development and milestones of $81 million primarily represented the research and development milestones of $70 million for our agreement with Henlius and $10 million for our agreement with Cirqle, which were determined to be probable of being achieved.”
FILING10-K0001628280-26-011125cik 0001821825
“Examples of current strategic collaborations include our license agreement with Organon to commercialize XACIATO, and our arrangements with Bravado Pharmaceuticals, LLC, under which it manufactures DARE to PLAY and fulfills prescription, and Medvantx, a pharmacy services provider, acting as a lo”
FILING10-K0001401914-26-000004cik 0001401914disclosed by DARE
“For the year ended December 31, 2024, acquired in-process research and development and milestones of $81 million primarily represented the research and development milestones of $70 million for our agreement with Henlius and $10 million for our agreement with Cirqle, which were determined to be probable of being achieved.”
FILING10-K0001628280-26-011125cik 0001821825
“For the year ended December 31, 2024, acquired in-process research and development and milestones of $81 million primarily represented the research and development milestones of $70 million for our agreement with Henlius and $10 million for our agreement with Cirqle, which were determined to be probable of being achieved.”
FILING10-K0001628280-26-011125cik 0001821825
“Sales for the year ended December 31, 2025, compared to 2024, declined 30%, due to competitive pressure in the United States, unfavorable pricing and lower tendered volume from Brazil's Ministry of Health when compared with 2024.”
FILING10-K0001628280-26-011125cik 0001821825
Watchlist prices, news filtered to it, and its next report on your desk.
Organon & Co. has 15 disclosed suppliers and 3 disclosed customers. Each one is named in an SEC filing, either Organon & Co.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
OGN (Organon & Co.) has 15 disclosed suppliers and 3 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move, and a bundle sits past the rings until you open it. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: XOMA −2.04%, in the health bundle.